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Classical driver mutations in acute myeloid leukemia (AML) typically affect regulators
of cell proliferation, differentiation, and survival. The selective advantage of increased
proliferation, improved survival, and reduced differentiation on leukemia progression is
immediately obvious. Recent large-scale sequencing efforts have uncovered numerous
novel AML-associated mutations. Interestingly, a substantial fraction of the most
frequently mutated genes encode general regulators of transcription and chromatin
state. Understanding the selective advantage conferred by these mutations remains a
major challenge. A striking example are mutations in genes of the cohesin complex,
a major regulator of three-dimensional genome organization. Several landmark studies
have shown that cohesin mutations perturb the balance between self-renewal and
differentiation of hematopoietic stem and progenitor cells (HSPC). Emerging data now
begin to uncover the molecular mechanisms that underpin this phenotype. Among
these mechanisms is a role for cohesin in the control of inflammatory responses in
HSPCs and myeloid cells. Inflammatory signals limit HSPC self-renewal and drive
HSPC differentiation. Consistent with this, cohesin mutations promote resistance to
inflammatory signals, and may provide a selective advantage for AML progression.
In this review, we discuss recent progress in understanding cohesin mutations in
AML, and speculate whether vulnerabilities associated with these mutations could be
exploited therapeutically.
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INTRODUCTION
Hematopoietic homeostasis requires tight regulation to ensure production of sufficient numbers
of blood cells at all stages of differentiation. This is achieved by a complex network of signaling
pathways and gene regulatory mechanisms that control cell proliferation, differentiation, and
survival of hematopoietic stem and progenitor cells (HSPC) and their progeny. Skewing of this
balance in favor of excessive differentiation results in stem cell depletion, exhaustion and eventually,
inability to replenish mature blood cells. In contrast, uncontrolled self-renewal, increased survival,
and failure to differentiate are hallmarks of leukemia.
The homeostatic balance between self-renewal and differentiation of HSPC is sensitive to a
broad range of perturbations. Mutations that disrupt it not only provide classifiers of clinical
disease, but also offer insights into the molecular control of self-renewal, differentiation, and cell
proliferation. Many AML-associated mutations are clearly linked to one of these categories, such
as constitutive activation of RAS proteins or FLT3, that drive uncontrolled proliferation (1–3),
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mutations that prevent cell cycle arrest and apoptosis such as
TP53 (4), and mutations that hinder differentiation such as in
the transcription factors RUNX1 or C/EBPα (5, 6). The clonal
advantage conferred by such mutations is immediately obvious.
Recent large-scale sequencing studies have shown that the
mutational landscape of AML is highly enriched for mutations
in general transcriptional regulators and chromatin modifiers,
which are found in ∼70% of patients (7). Examples of this
group include mutations in proteins involved in chromatin
modifications (ASXL1, EZH2), DNA methylation (DNMT3A,
TET2), or transcriptional splicing (SRSF2, U2AF1) (7–9).
Although we understand the biological functions of many
of these molecules and pathways in exquisite detail, their
selective advantage for AML cells remains largely unknown (10).
Understanding the link between these novel AMLmutations and
the molecular mechanisms of self-renewal, differentiation and
cell survival is critical for understanding the pathophysiology of
AML, and for the identification of new therapeutic approaches to
cancer (Figure 1).
A striking example are mutations in the subunits of the
cohesin protein complex (SMC1, SMC3, RAD21, and STAG1/2).
Cohesin forms a ring-shaped structure that can encircle DNA
and hold sister chromatids together. This function of cohesin
is essential for DNA replication (11–13), DNA repair (14–
17), and chromosome segregation in mitosis (18–20). Despite
this essential role in cell cycle progression, heterozygous
or hypomorphic cohesin mutations are compatible with cell
FIGURE 1 | Classical and non-classical AML mutations. (A) Classical AML
mutations deregulate proliferation, survival and differentiation pathways and
provide an obvious selective advantage to AML. (B) Novel AML mutations
include mutations in transcription and chromatin regulators and their selective
advantage is less obvious.
proliferation (21). This explains how leukemic cells can tolerate
cohesin mutations, but fails to explain why cohesin mutations
occur with high frequencies in AML.
In addition to essential functions in the cell cycle, cohesin
has a major role in three-dimensional genome organization
(22). Cohesin cooperates with the DNA-binding protein CTCF
in the formation of topologically associated domains (TADs),
which facilitate preferential interactions between genes and
enhancers within the same CTCF-demarcated domain (23–26).
Impaired formation of these structures randomizes the three-
dimensional topology across single cells (27), thus exposing genes
and enhancers to illegitimate interactions (28).
Here we review recent progress that links impaired cohesin
function to the regulation of inflammatory gene expression,
self-renewal, and differentiation of hematopoietic progenitors
(29–34), revealing potential explanations for why cohesin is
recurrently mutated in AML. We speculate about the role
of inflammatory gene expression in AML and its potential
therapeutic implications.
COHESIN MUTATIONS IN AML
Mutations in members of the cohesin complex are found
in 6–13% of AML cases (7, 35–37). In addition to AML,
cohesin mutations are also found in other myeloid
malignancies, including Down syndrome acute megakaryoblastic
leukemia (DS-AMKL), myelodysplastic syndrome (MDS),
myeloproliferative neoplasms (MPN), chronic myelomonocytic
leukemia (CMML), and chronic myelogenous leukemia (CML)
(38, 39). Cohesin mutations are frequent in myeloid but not
in lymphoid malignancies, suggesting that the pro-leukemic
effect of reduced cohesin function may be connected to
myeloid-specific traits.
The majority of RAD21 and STAG2 mutations cause non-
sense, frame-shift, or splice-site changes, presumably leading
to protein truncation or exon skipping. On the other hand,
mutations in SMC1A and SMC3 are missense, causing amino
acid substitutions in different protein domains (38). The effect of
each of these mutations on the formation of the cohesin complex
is still largely unexplored. Some of the mutant transcripts can
give rise to dominant-negative proteins in cord blood progenitors
(32) while others result in the degradation of the mutant
transcript (38).
Most cohesin mutations are heterozygous, consistent with the
idea that complete loss of the complex is incompatible with cell
cycle progression. This has been confirmed by studies showing
that partial cohesin loss in AML cells is not linked to increased
aneuploidy (29, 36, 38, 40). However, since the Stag2 and Smc1a
genes are on the X chromosome, male cases with mutations
in these genes are not heterozygous. In the case of STAG2
mutant cells it has been shown that STAG1 becomes essential
(41), suggesting that loss of STAG2 can be at least partially
compensated by STAG1.
Cohesinmutations in patients appear to bemutually exclusive,
indicating that a mutation in just one member of the complex
is sufficient to reduce cohesin activity to the point where it
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provides a clonal advantage. Cohesin mutations often co-occur
with mutations in other genes, such as NPM1, TET2, ASXL1,
and EZH2 (36, 38). Nonetheless, it is thought that the majority
of cohesin mutations are early events in leukemogenesis (38, 42).
The prognostic significance of cohesin mutations in myeloid
malignancies is not yet fully clear. In MDS, STAG2 mutations are
associated with significantly reduced survival (37). However, no
significant association between cohesinmutations and survival in
AML was found in an early study (36) while a more recent study
reports a significant association with increased overall survival
and disease-free survival (43).
THE ROLE OF COHESIN EARLY
HEMATOPOIESIS
The frequency of cohesin mutations in AML prompted several
groups to investigate the contribution of cohesin to early
hematopoiesis and myeloid differentiation (Table 1). A mouse
model of conditional Smc3 heterozygosity (31) presented an
altered composition of the hematopoietic stem cell (HSC)
compartment. Short-term HSCs and multipotent progenitor
populations (MPP) were increased, while in long-term HSCs
were decreased (31). In competitive repopulation assays, cohesin-
deficient cells outcompeted wild-type cells. An important aspect
of this study was the demonstration that Smc3 heterozygosity
on its own is not sufficient to trigger leukemic transformation.
However, the combination of Smc3 heterozygosity and an
internal duplication in the FLT3 receptor (one of the most
common mutations in AML) induced acute myeloid leukemia in
mice. This indicates that SMC3 mutations must cooperate with
other mutations to cause leukemia in this model. However, a
mouse model of conditional Stag2 deletion presented features
of myeloid dysplasia (44). Also, these mice had increased
frequencies of both long-term and short-term HSC, indicating
that mutations in different cohesin subunits do not always cause
the same phenotypes.
Mouse models of shRNA-mediated knock-down of different
cohesin subunits developed similar, but not identical alterations
in stem cell compartments (30). In the bone marrow there
was a marked increase in granulocyte-macrophage progenitors
(GMP), accompanied by a decrease in long-term and short-term
HSCs. These models of cohesin deficiency did not develop acute
myeloid leukemia. However, the mice displayed several features
resembling a myeloid disorder, including splenomegaly and
myeloid hyperplasia. In addition, cohesin-mutated mouse cells
TABLE 1 | Main phenotypes and transcriptional changes in models of cohesin depletion in hematopoiesis.
Model Main phenotypes of cohesin depletion Transcriptional changes References
Mouse model of conditional
Smc3 heterozygous deletion
Mx1-Cre; Smc3lox/WT
Increase in ST-HSC and MPP and decrease in LT-HSC
Increased bone marrow chimerism in competitive transplantation
assays
Absence of leukemic transformation unless combined with Flt3
mutations
Increased self-renewal in methylcellulose assays
Deregulation of lineage-specific transcription factors
Global reduction in transcription
(31)




Increase in ST-HSC, LT-HSC, MPP, and GMP
Increased bone marrow chimerism in competitive transplantation
assays
Blockade in B-cell differentiation
Downregulation of lymphoid, myeloid and erythroid
lineage commitment genes





expression for Rad21, Smc1a,
and Stag2 TRE-shRNA;
ROSA26(M2rtTA/+)
Decrease in ST and LT-HSC and increase in GMP
Myeloid disorder features (splenomegaly and myeloid hyperplasia)
Increased self-renewal in methylcellulose assays
Upregulation of myeloid differentiation genes (Fcgr3,
Cebpa)
Downregulation of lymphoid development genes
(Blnk, Lax1, Cd86)
(30)
Human CD34+ cord blood cells
transduced with mutant cohesin
genes (RAD21E212*,
RAD21Q592*, SMC1A R711G )
Impaired sensitivity to cytokine-induced differentiation
Increase in CD34+ progenitors after engraftment in NSG mice
Increased self-renewal in methylcellulose assays
Upregulation of HSC genes (HOX genes, MEIS1)
Downregulation of myeloid differentiation genes
(MPO, CSF1R)
(32)
Human CD34+ cord blood cells
transduced with shRNASTAG2
Delayed differentiation and expansion of immature cells over time
after engraftment in NSG mice
Increased self-renewal in methylcellulose assays
Upregulated genes enriched in HSC-specific genes (33)
Mouse HSPCs transduced with
shRNARad21






Decrease in LPS-induced differentiation
Impaired inducible gene expression
Downregulation of tonic interferon expression
(34)
Mouse HSPCs transduced with
shRNARad21 and mouse models
of conditional Rad21 deletion
Mx-Cre; Rad21lox/+
Decrease in LPS-induced differentiation
Positive selection of Rad21-deficient HSCs during aging
Inhibited NFkB transcriptional response (45)
* indicates nonsense mutations.
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acquire increased self-renewal capacity in in vitromethylcellulose
colony formation assays.
Importantly, similar results were obtained with human cells
(32, 33). Cohesin-deficient cord blood progenitors or AML
cell lines displayed reduced sensitivity to the differentiation-
inducing effects of cytokines. The same effect was observed
by over-expressing cohesin genes carrying mutations identified
in AML, indicating that these can act as dominant-negative
mutants. These cells were also characterized by a higher
frequency of CD34+ progenitors and increased self-renewal
capacity in methylcellulose (32). In line with these findings,
cohesin-deficient human blood progenitors have increased
in vivo reconstitution capacity after transplantation into
immunodeficient mice (33).
TRANSCRIPTIONAL CONSEQUENCES OF
COHESIN MUTATIONS IN HSPCS
Given that AML-associated cohesin mutations do not affect
genome integrity (38), the observed resistance to differentiation
has been ascribed to the gene regulatory role of cohesin. In all
models tested, transcriptional changes were mild (31, 32). This is
expected, as even complete removal of cohesin only changes the
expression of 10% of genes (23).
Previous reports suggested a role for cohesin in facilitating
chromatin remodeling in human and mouse cells (46, 47).
Consistent with this, cohesin-deficient HSPCs present genome-
wide alterations in chromatin accessibility (30–33, 45). These
changes broadly correlate with altered gene expression.
Therefore, it has been proposed that defective chromatin
accessibility impacts on normal dynamics of transcription
factor binding, which leads to transcriptional deregulation and
abnormal differentiation.
An extreme case of chromatin alterations was observed in
human cord blood cells, where dominant negative cohesin
mutations reduced chromatin accessibility genome-wide (32).
Interestingly, a minority of sites displayed increased accessibility,
specifically binding sites for the transcription factors GATA2 and
RUNX1. This has been proposed to result in an upregulation of
HSPC transcriptional programs and obstruct differentiation. A
role for cohesin in regulating RUNX1 expression has also been
described in model organisms (48).
How is cohesin linked to chromatin accessibility? Cohesin
binding sites are highly accessible (49). In yeast, cohesin
cooperates with the chromatin structure remodeling complex
(RSC) to actively evict nucleosomes and generate nucleosome-
free DNA (50–52), which is required for cohesin loading (53).
In mouse embryonic stem cells, depletion of a member of the
PBAF complex (a vertebrate ortholog of RSC) results in sister-
chromatid cohesion defects (54). In humans, cohesin is found
in a complex with the ATP-dependent chromatin remodeling
enzyme SNF2H (55). SNF2H, but not cohesin, is required for
the establishment of arrays of phased nucleosomes around CTCF
binding sites (56).
Reduced cohesin dosage can also alter the frequency of
chromatin interactions near transcription factor genes. One
example is the transcriptional regulation of the lymphoid
transcription factor Ebf1, that has four STAG2 binding sites in
hematopoietic progenitors. In Stag2−/− mice, cis-interactions at
this locus are lost, leading to abrogation of Ebf1 expression and
failure to differentiate into lymphoid progenitors (44).
Another mechanism that has been proposed to explain the
increased self-renewal capacity of cohesin-deficient HSPCs is
the derepression of the self-renewal transcription factor HOXA9
(29, 57). HOXA9 is normally silenced by the Polycomb complex,
which represses Hox loci in HSPCs by H3K27 trimethylation.
In cohesin-deficient mouse HSPCs, this repressive chromatin
mark is lost and Hoxa9 is upregulated, leading to increased
self-renewal. This finding suggests that cohesin cooperates with
Polycomb to silenceHox genes in HSPCs. Consistently, in mouse
embryonic stem cells, cohesin complexes containing STAG2
(but not STAG1) contribute to the maintenance of chromatin
interactions within Polycomb domains (58).
COHESIN IN THE CONTROL OF THE
INFLAMMATORY RESPONSE
As discussed in the previous section, all studies that have
compared wild-type and cohesin-deficient HSPCs found
clear changes in chromatin accessibility and gene expression.
These changes may indicate a direct effect of cohesin, or,
alternatively, they may reflect the less mature state of cohesin-
deficient progenitor populations. In order to rule out this
possibility and determine what genes are directly controlled
by cohesin in myeloid cells, a recent study used terminally
differentiated macrophages to allow a like-for-like comparison
of transcriptional and chromatin state between wild-type and
cohesin-deficient cells (34). This strategy uncovered a key role
for cohesin in the regulation of inflammatory gene expression.
Consistent with a body of knowledge demonstrating that cohesin
is required for interactions within topological domains (23–26),
interactions between upstream key transcriptional regulators
of the inflammatory response and their surrounding enhancers
were decreased after acute cohesin depletion. As the organization
of the inflammatory response is hierarchical, reduced levels of
upstream regulators impact on the network, and deregulation
spreads to the majority of inducible genes. Importantly, re-
analysis of HSPC gene expression data showed that cohesin also
controls inflammatory gene expression in progenitor cells (34).
Inflammatory signals not only mediate cross-talk between
immune cells to coordinate the immune response, but
also regulate the balance between HSPC self-renewal
and differentiation. This function, known as emergency
hematopoiesis, is normally activated during infection in order
to regenerate mature myeloid cell populations (59). Several
inflammatory cytokines and ligands, including interferons, are
involved in the activation of emergency hematopoiesis. Type I
interferon induces HSC exit from quiescence, entry into the cell
cycle and differentiation. Importantly, chronic exposure to type I
interferon is detrimental to HSCs (60, 61). Type II interferon—
or IFNγ–also regulates HSC activity both in homeostasis and
during infection (62). IFNγ acts on a subset of HSCs to induce
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myeloid differentiation by activating transcription factors
like C/EBPβ (63). The interleukin IL-1 brings about myeloid
differentiation through activation of a NF-κB-PU.1 axis (64).
Activation of Toll-like receptor (TLR) signaling in HSPCs,
which activates both the NF-κB and the interferon pathways,
also promotes myeloid differentiation (65–69). As in the case of
chronic interferon exposure, sustained TLR activation becomes
detrimental and impairs the repopulating capacity of HSPCs.
As cohesin is required to induce expression of inflammatory
response genes, cohesin-deficient HSPCs are less prone to
differentiate in inflammatory conditions [(34, 45); Figure 2].
This acquired resistance to differentiation allows increased
proliferation of immature progenitors, providing a possible
explanation for some of the phenotypes displayed by cohesin-
deficient mice. Therefore, cohesin mutations in AML illustrate a
mechanistic connection between the control of transcriptional
regulation and the responsiveness to differentiation-inducing
stimuli in myeloid cells. The selective advantage of mutations
in other transcriptional regulators may potentially be
explained by similar mechanisms involving the control of
inflammatory signaling.
INFLAMMATORY GENE EXPRESSION IN
AML
Consistent with the finding that cohesin regulates inflammatory
gene expression in hematopoietic progenitors and myeloid cells,
AML patient cells with cohesin mutations show a striking
reduction of inflammatory and interferon pathways. This is the
case when comparing AML with and without cohesin mutations
across all samples in The Cancer Genome Atlas (TCGA), as well
as within a specific histological subtype (34). These data suggest
that the same mechanism that favors self-renewal in cohesin-
deficient HSPCs through impaired sensitivity to inflammatory
signals may operate in cohesin-deficient AMLs. The implication
is that in settings with increased inflammatory signaling, cohesin
mutations could confer resistance to inflammatory signals and
increased self-renewal and clonal expansion.
Constitutively increased inflammatory signals are a hallmark
of aging. Basal levels of pro-inflammatory cytokines such as IL6
or TNFα increase with age in healthy individuals (70). This
leads to alterations in hematopoietic differentiation, which are
reminiscent of emergency hematopoiesis: myelopoiesis-biased
differentiation and reducedHSC self-renewal (71, 72). Consistent
with its role in conferring resistance to inflammatory signals,
competitive assays show that cohesin mutant HSCs become
dominant over wild-type HSCs in aged mice (45). As clonal
hematopoiesis is a feature of aging (73), it has been suggested
that cohesin mutations could be positively selected during aging,
eventually promoting a pre-leukemic state (45). This is in line
with a report showing that cohesin mutations are early events,
considered to be pre-leukemic (42). However, cohesin subunits
are not among the top frequently mutated genes in cases where
clones of hematopoietic cells carrying somatic mutations are
found in the absence of any hematologic dysplasia, known as
clonal hematopoiesis of indeterminate potential (CHIP) (73).
Therefore, the emergence of cohesin mutations associated to
aging may immediately lead to pre-leukemic dysplasias rather
than CHIP. Further investigation is required to understand the
role of cohesin mutations during aging.
A number of previous studies have reported altered
expression of cytokines and other inflammatory mediators in
myeloid disorders (74–76). For example, FLT3-ITD+ AML show
increased expression of microRNA miR-155, which is known
FIGURE 2 | Cohesin regulates the balance between self-renewal and differentiation. Cohesin controls expression of pro-inflammatory genes that promote HSPC
differentiation. In cohesin-mutant AML, inflammatory gene expression is downregulated, increasing resistance to differentiation and favoring HSPC self-renewal.
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for its anti-inflammatory effects, its ability to inhibit interferon
signaling, and to increase HSPC self-renewal in mouse models
(77). Sensitivity of human AML cells to IFNγ is inversely related
to RIP1/3 signaling. High levels of RIP1/3 signaling stabilize
SOCS1, and SOCS1 antagonizes IFNγ signaling, effectively
protecting AML cells from the differentiation-inducing effects
of IFNγ (78). On the other hand, reduced RIPK3 expression
is thought to reduce differentiation and TNFR-driven death of
AML cells (79). Interleukin-1 (IL-1) inhibits growth of normal
hematopoietic progenitors, but promotes expansion of AML cells
by increasing p38 MAPK phosphorylation. This effect can be
reversed by blocking IL-1 with p38 MAPK inhibitors (80).
As an illustration of the complexity of the pathways involved
in the regulation of inflammation and differentiation, TNF
activates NFκB via JNK in AML cells (81) and can dampen
interferon signaling via SOCS1 (78). NFκB is constitutively
activated in CD34+CD38− AML cells (82), promoting leukemia
stem cell survival and proliferation (77). Although exogenous
interferon reduces in vitro self-renewal induced by RUNX1-
ETO and RUNX1-ETO9a, interferon and interferon-stimulated
genes are elevated by RUNX1-ETO in human and in murine
models (83). Finally, the chromatin modifier TET2 is required
for emergency myelopoiesis (84), and TET2 mutants show
greater fitness in inflammatory environments partially due to
increased resistance to TNF, which triggers IL6 overproduction
and activation of an anti-apoptotic lncRNA (85, 86). Taken
together, these studies link myeloid disorders with inflammation
and indicate that AML may use a spectrum of different strategies
for managing inflammatory signals.
INTERFERON TREATMENT IN AML
The interferon pathway is central to the inflammatory gene
expression network, and it is heavily deregulated in cohesin-
deficient macrophages (34). The deregulation of upstream
interferon regulators like STAT1 and IRF7 disrupts basal
interferon secretion, which maintains anti-viral transcriptional
responsiveness by auto- and paracrine feed-forward signaling
(87, 88). In the absence of cohesin, STAT and IRF-dependent
enhancers fail to be induced, and consequently most interferon-
induced genes are deregulated. Importantly, both enhancer
activation and constitutive interferon gene expression can
be partially rescued with exogenous interferon (34). These
findings provide grounds to speculate that cohesin-mutated
AMLs could be particularly vulnerable to interferon treatment.
Mechanistically, supplying exogenous interferon could partially
rescue expression of upstream transcription factors and
regulators of the pathway, enabling normal enhancer activation,
and transcription of downstream effectors. This would in turn
increase the inflammatory responsiveness of cohesin-mutant
AML cells, potentially restoring the balance between self-renewal
and differentiation and restricting their selective advantage.
There is a long history of using type I interferons to
treat hematological malignancies, with varying degrees of
success. While early studies were hampered by treatment
limiting side-effects, more recent recombinant and pegylated
preparations are tolerated much better and can be used
with feasible dosing regimens. There are currently established
roles for interferon in the myeloproliferative disorders (89,
90), hypereosinophilic syndromes (91), and chronic myeloid
leukemia (CML) (92). Intriguingly in CML, interferon treatment
appears to preferentially target the leukemic stem cell population,
and can induce cytogenetic remissions, some of which are
durable upon treatment withdrawal, suggesting that it can cure
some patients (92). Similar effects are observed in the JAK2
myeloproliferative disorders, with reduction or clearance of the
mutant clones in up to 50% of patients (93).
In acute leukemia, interferon treatment impairs proliferation
of AML cell lines in vitro, and has anti-leukemic effects in
patient-derived xenograft models (PDX) in a dose dependent
manner (94). This has been explained by cell intrinsic
effects of interferon on leukemic blasts (reduced proliferation,
increased apoptosis, and reduced secretion of growth-promoting
cytokines), increased immunogenicity of interferon-treated
leukemic blasts, as well as immunomodulatory effects on the
residual normal hematopoietic cells, and increased clearance by
the host immune system. However, despite the encouraging pre-
clinical data, the clinical outcomes in interferon trials in AML
have been disappointing, with durable responses seen in only
small percentage of patients. While patients with secondary AML
arising from amyeloproliferative disorder seemmost susceptible,
this is not exclusively the case. However, much of the clinical
experience pre-dates the availability of current sequencing
technologies and so stratification of AML bymutationmay reveal
genetic susceptibilities to interferon treatment.
CONCLUSIONS
Many recently identified AML mutations are in genes encoding
regulators of transcription and chromatin state. Understanding
how these mutations are beneficial to cancer cell fitness is a
major challenge (10). Regulators of transcription and chromatin
state usually regulate the expression of hundreds or thousands of
genes, which complicates the task of pinpointing the target genes
that are responsible for the increased fitness of mutated cells.
Mutations in subunits of the cohesin complex result in
clear alterations in the hematopoietic stem cell compartment
and in HSPC function (29–33, 45). However, the specificity of
cohesin control on HSPC gene expression has been difficult to
accommodate with current models of cohesin function.
The transcriptional control of inducible gene expression
provides a possible explanation for the high frequency of cohesin
mutations in myeloid malignancies. Inflammatory signaling
promotes the differentiation of HSPCs toward a myeloid fate
(59), and cohesin-deficient cells show increased resistance to
these differentiation-inducing stimuli (34, 45). In bone marrow
microenvironments with alterations in cytokine levels such as
those found in aging (70), myelodysplastic syndrome (MDS)
(95) or leukemia (75, 76), mutations that confer reduced
responsiveness to differentiation-inducing signals are likely to
be positively selected and clonally expanded (45). This is
consistent with observations that cohesin mutations appear early
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in the history of AML (42), and that cohesin mutations by
themselves alter the composition of the HSPC compartment but
are insufficient to trigger AML (31).
AML has an inherently poor prognosis, and even
with intensive chemotherapy or hematopoietic stem cell
transplantation the risk of relapse remains high. AML is a highly
heterogeneous disease by morphological, clinical, and genetic
criteria, underlining the need for targeted approaches. For a
subset of recurrent mutations, such as FLT3, specific inhibitors
are in clinical use (2). For others, like cohesin mutations,
greater understanding of the molecular circuitries involved
in the increased fitness of mutated cells is necessary to find
vulnerabilities and new therapeutic approaches.
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